Journal of Hematology & Oncology (2024)

CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update Mortality of lymphoma and myeloma in China, 2004–2017: an observational study The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia Natural killer cells in clinical development as non-engineered, engineered, and combination therapies Advances in the assessment of minimal residual disease in mantle cell lymphoma Novel therapeutic agents for cutaneous T-Cell lymphoma A precision medicine classification for treatment of acute myeloid leukemia in older patients Current trials for frontline therapy of mantle cell lymphoma Novel target and treatment agents for natural killer/T-cell lymphoma Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies Mutational profiling of acute lymphoblastic leukemia with testicular relapse Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia Evidence-based expert consensus on the management of primary central nervous system lymphoma in China Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia Update in the management of chronic lymphocytic leukemia Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT New targets for the treatment of follicular lymphoma Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma Burden of lymphoma in China, 2006–2016: an analysis of the Global Burden of Disease Study 2016 Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) Ganoderma lucidum polysaccharides can induce human monocytic leukemia cells into dendritic cells with immuno-stimulatory function Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors Targeting macrophages in hematological malignancies: recent advances and future directions Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990–2019 Functional and genetic screening of acute myeloid leukemia associated with mediastinal germ cell tumor identifies MEK inhibitor as an active clinical agent Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study Conventional and novel [18F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives Notch1-induced T cell leukemia can be potentiated by microenvironmental cues in the spleen IGF binding protein 2 is a cell-autonomous factor supporting survival and migration of acute leukemia cells Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies Role of CD47 in Hematological Malignancies Targeting p53 by small molecules in hematological malignancies IGF-IR determines the fates of BCR/ABL leukemia Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies